Effectiveness and Safety of Intracavernosal IncobotulinumtoxinA (Xeomin®) 100 U as an Add-on Therapy to Standard Pharmacological Treatment for Difficult-to-Treat Erectile Dysfunction: A Case Series
This 2022 case series evaluated the safety and efficacy of intracavernosal injection (ICI) of incobotulinumtoxinA (Xeomin®) 100 U as an adjunct to standard pharmacological treatments (PDE5 inhibitors or PGE1 ICIs) in 66 men with difficult-to-treat erectile dysfunction (ED). Approximately 52% of patients achieved a clinically meaningful improvement in International Index
June 26, 2025
No Comments